Your browser doesn't support javascript.
loading
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?
Ercoli, Tommaso; Tinazzi, Michele; Geroin, Christian; Marcuzzo, Enrico; Erro, Roberto; Cuoco, Sofia; Ceravolo, Roberto; Mazzucchi, Sonia; Pilotto, Andrea; Padovani, Alessandro; Romito, Luigi Michele; Eleopra, Roberto; Zappia, Mario; Nicoletti, Alessandra; Dallocchio, Carlo; Arbasino, Carla; Bono, Francesco; Spano, Giorgio; Demartini, Benedetta; Gambini, Orsola; Modugno, Nicola; Olivola, Enrica; Bonanni, Laura; Albanese, Alberto; Ferrazzano, Gina; Tessitore, Alessandro; Lopiano, Leonardo; Calandra-Buonaura, Giovanna; Petracca, Martina; Morgante, Francesca; Esposito, Marcello; Pisani, Antonio; Manganotti, Paolo; Tesolin, Lucia; Teatini, Francesco; Stocchi, Fabrizio; Defazio, Giovanni.
Afiliação
  • Ercoli T; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Tinazzi M; Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy. michele.tinazzi@univr.it.
  • Geroin C; Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy. christian.geroin@univr.it.
  • Marcuzzo E; Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy.
  • Erro R; Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
  • Cuoco S; Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
  • Ceravolo R; Center for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Mazzucchi S; Center for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Pilotto A; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Padovani A; FERB Onlus, Ospedale S. Isidoro, Trescore Balneario, Bergamo, Italy.
  • Romito LM; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Eleopra R; Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Zappia M; Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Nicoletti A; Department G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.
  • Dallocchio C; Department G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.
  • Arbasino C; Department of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.
  • Bono F; Department of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.
  • Spano G; Botulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.
  • Demartini B; Botulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.
  • Gambini O; Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.
  • Modugno N; Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.
  • Olivola E; IRCCS Neuromed, Pozzilli, Italy.
  • Bonanni L; IRCCS Neuromed, Pozzilli, Italy.
  • Albanese A; Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio, Chieti-Pescara, Italy.
  • Ferrazzano G; Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Tessitore A; Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.
  • Lopiano L; Department of Advanced Medical and Surgery Sciences, University of Campania-Luigi Vanvitelli, Naples, Italy.
  • Calandra-Buonaura G; Department of Neuroscience-Rita Levi Montalcini, University of Turin, Turin, Italy.
  • Petracca M; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Morgante F; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Esposito M; Movement Disorder Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Pisani A; Neurosciences Research Centre, Molecular and Clinical Sciences Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
  • Manganotti P; Department of Experimental and Clinical Medicine, University of Messina, Messina, Italy.
  • Tesolin L; Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
  • Teatini F; IRCCS Mondino Foundation, Pavia, Italy.
  • Stocchi F; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
  • Defazio G; Clinical Neurology Unit, Department of Medical, Surgical and Health Services, University of Trieste, Trieste, Italy.
J Neural Transm (Vienna) ; 129(10): 1271-1276, 2022 10.
Article em En | MEDLINE | ID: mdl-35972697
The aim of this study is to assess changes in the body distribution and the semeiology of functional motor disorder (FMD) in patients who reported only one or more than one body site affected at FMD onset. Data were obtained from the Italian Registry of Functional Motor Disorders, which included patients with a diagnosis of clinically definite FMDs. The relationship between FMD features and spread to other body sites was estimated by multivariate Cox regression analysis. We identified 201 (49%) patients who reported only one body site affected at FMD onset and 209 (51%) who reported multiple body sites affected at onset. FMD spread from the initial site to another site in 43/201 (21.4%) patients over 5.7 ± 7.1 years in those with only one site affected at FMD onset; FMD spread to an another body site in 29/209 (13.8%) over 5.5 ± 6.5 years. The spread of FMD was associated with non-motor functional symptoms and psychiatric comorbidities only in the patients with one body site affected at FMD onset. Our findings provide novel insight into the natural history of FMD. The number of body sites affected at onset does not seem to have a consistent influence on the risk of spread. Furthermore, our findings suggest that psychiatric comorbidities and non-motor functional symptoms may predict the spread of FMD symptoms, at least in patients with one body site affected at onset.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Motores / Transtornos dos Movimentos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Motores / Transtornos dos Movimentos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article